Piper Sandler & Co’s Travere Therapeutics TVTX Stock Holding History

Piper Sandler & Co’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-337	Closed	-$4K	–	165
2014 Q2	$4K	Buy	+337	New	+$4.57K	﹤0.01%	116

Other funds holding TVTX

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

Piper Sandler & Co's TVTX Position: Q3 2014 in Review

Piper Sandler & Co sold out of Travere Therapeutics (TVTX) in Q3 2014, closing a stake of 337 shares — an estimated $4K sold.

Piper Sandler & Co first reported a position in TVTX in Q2 2014 and held it in 1 quarter. The position peaked at $4K in Q2 2014. 60 funds tracked by Wall St. Rank hold TVTX as of Q3 2014.

Piper Sandler & Co reported no remaining Travere Therapeutics position as of Q3 2014 after selling out during the quarter.
Piper Sandler & Co sold 337 Travere Therapeutics shares in Q3 2014, an estimated $4K.
Piper Sandler & Co first reported a position in Travere Therapeutics in Q2 2014 and held it in 1 quarter.
Piper Sandler & Co's Travere Therapeutics position peaked at $4K in Q2 2014.
60 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2014.

Based on Piper Sandler & Co's 13F filing for Q3 2014, filed 14 Nov 2014.